Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Accured Expenses (2022 - 2026)

Centessa Pharmaceuticals has reported Change in Accured Expenses over the past 4 years, most recently at $12.1 million for Q4 2025.

  • Quarterly Change in Accured Expenses fell 62.91% to $12.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.2 million through Dec 2025, down 166.82% year-over-year, with the annual reading at -$15.2 million for FY2025, 166.82% down from the prior year.
  • Change in Accured Expenses was $12.1 million for Q4 2025 at Centessa Pharmaceuticals, up from -$689000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $32.7 million in Q4 2024 and troughed at -$29.6 million in Q1 2025.
  • The 4-year median for Change in Accured Expenses is $2.3 million (2022), against an average of $813687.5.
  • The largest YoY upside for Change in Accured Expenses was 1501.47% in 2024 against a maximum downside of 2706.12% in 2024.
  • A 4-year view of Change in Accured Expenses shows it stood at -$4.8 million in 2022, then surged by 142.28% to $2.0 million in 2023, then skyrocketed by 1501.47% to $32.7 million in 2024, then plummeted by 62.91% to $12.1 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Change in Accured Expenses are $12.1 million (Q4 2025), -$689000.0 (Q3 2025), and $2.9 million (Q2 2025).